###begin article-title 0
Arthritis suppression by NADPH activation operates through an interferon-beta pathway
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10116">rats</span>
###xml 554 558 <span type="species:ncbi:10116">rats</span>
A polymorphism in the activating component of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, neutrophil cytosolic factor 1 (NCF1), has previously been identified as a regulator of arthritis severity in mice and rats. This discovery resulted in a search for NADPH oxidase-activating substances as a potential new approach to treat autoimmune disorders such as rheumatoid arthritis (RA). We have recently shown that compounds inducing NCF1-dependent oxidative burst, e.g. phytol, have a strong ameliorating effect on arthritis in rats. However, the underlying molecular mechanism is still not clearly understood. The aim of this study was to use gene-expression profiling to understand the protective effect against arthritis of activation of NADPH oxidase in the immune system.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 784 789 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf-1</italic>
###xml 789 792 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DA </italic>
###xml 789 792 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DA </italic></sup>
###xml 869 874 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf-1</italic>
###xml 874 877 867 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 890 894 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 894 897 887 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 770 773 <span type="species:ncbi:10116">rat</span>
###xml 877 880 <span type="species:ncbi:10116">rat</span>
Subcutaneous administration of phytol leads to an accumulation of the compound in the inguinal lymph nodes, with peak levels being reached approximately 10 days after administration. Hence, global gene-expression profiling on inguinal lymph nodes was performed 10 days after the induction of pristane-induced arthritis (PIA) and phytol administration. The differentially expressed genes could be divided into two pathways, consisting of genes regulated by different interferons. IFN-gamma regulated the pathway associated with arthritis development, whereas IFN-beta regulated the pathway associated with disease protection through phytol. Importantly, these two molecular pathways were also confirmed to differentiate between the arthritis-susceptible dark agouti (DA) rat, (with an Ncf-1DA allele that allows only low oxidative burst), and the arthritis-protected DA.Ncf-1E3 rat (with an Ncf1E3 allele that allows a stronger oxidative burst).
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf-1 </italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf-1 </italic>
###xml 701 706 691 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 434 438 <span type="species:ncbi:10116">rats</span>
Naturally occurring genetic polymorphisms in the Ncf-1 gene modulate the activity of the NADPH oxidase complex, which strongly regulates the severity of arthritis. We now show that the Ncf-1 allele that enhances oxidative burst and protects against arthritis is operating through an IFN-beta-associated pathway, whereas the arthritis-driving allele operates through an IFN-gamma-associated pathway. Treatment of arthritis-susceptible rats with an NADPH oxidase-activating substance, phytol, protects against arthritis. Interestingly, the treatment led to a restoration of the oxidative-burst effect and induction of a strikingly similar IFN-beta-dependent pathway, as seen with the disease-protective Ncf1 polymorphism.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 692 693 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 953 954 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1093 1094 1089 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1095 1097 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis (RA) is one of the commonest autoimmune diseases, with a prevalence of 0.5-1% [1,2]. RA is a chronic and severely disabling disease of unknown etiology, although both environmental [3] and genetic factors [4] are believed to play roles in its cause. There is presently no cure for RA, although a variety of different drugs is used to treat the symptoms. The most common treatments include disease-modifying antirheumatic drugs such as,methotrexate [5,6]. Other efficient antirheumatic drugs are the recently developed biological-response modifiers, such as tumor necrosis factor (TNF)-alpha blockers, which reduce both the established inflammation and joint destruction [7]. The drawback of these treatments is an increased risk of infections because the body's defense system is impaired. Other biological-response modifiers targeting other cytokines or costimulatory molecules are currently being clinically tested and evaluated [8]. Despite this range of antirheumatic drugs, there is still a large number of RA patients for whom none of these treatments is effective [9,10], thus making the development of new therapies essential.
###end p 9
###begin p 10
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 221 226 <span type="species:ncbi:9606">human</span>
Identification of new targets for development of antirheumatic drugs is hampered by the heterogeneity of RA and the complexity of its molecular pathology. However, recent efforts with linkage-association studies, both in human populations and in animal models, are now giving results in the form of successful identification of autoimmunity-regulating genes [11-15]. The combined results from such studies will eventually lead to a greater understanding of the molecular regulation of this complex disease and they present potential new targets for drug development.
###end p 10
###begin p 11
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neutrophil cytosolic factor 1 </italic>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p47phox</italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3</sup>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 851 856 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 232 236 <span type="species:ncbi:10116">rats</span>
###xml 302 305 <span type="species:ncbi:10116">rat</span>
Neutrophil cytosolic factor 1 (Ncf1), also known as p47phox, was one of the first single genes identified to regulate arthritis severity. This finding was a result of linkage analysis and positional cloning in an arthritis model in rats using a cross between the arthritis-susceptible dark agouti (DA) rat and the arthritis-resistant E3 strains DA.Ncf1E3([14,16]. NCF-1 is the activating component of the NADPH oxidase complex, which, upon activation, produces reactive oxygen species (ROS) [17]. We found that the dramatic increase in arthritis severity was caused by a decreased capacity of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex to produce ROS. Interestingly, the lower oxidative burst led to a reduction in cell membrane proteins and activation of autoreactive and arthritogenic T cells [18]. Thus, the identified Ncf1 polymorphism and its effect on the immune system by decreased ROS production was concluded to be associated with the regulation of arthritogenic CD4 T cells in the immune priming phase [14,19].
###end p 11
###begin p 12
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 255 259 <span type="species:ncbi:10116">rats</span>
NADPH oxidase-activating substances such as phytol (3,7,11,15-tetramethyl-2-hexadecene-1-ol), were identified from studies performed on a human neutrophil cell line, and have subsequently been shown to be very efficacious in the treatment of arthritis in rats [20]. However, the mechanism through which these compounds act is still not completely understood.
###end p 12
###begin p 13
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 245 253 245 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 1193 1196 1193 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 1411 1415 1411 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 1415 1418 1415 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 1588 1592 1588 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 175 179 <span type="species:ncbi:10116">rats</span>
###xml 938 942 <span type="species:ncbi:10116">rats</span>
###xml 966 970 <span type="species:ncbi:10116">rats</span>
###xml 1205 1209 <span type="species:ncbi:10116">rats</span>
###xml 1364 1367 <span type="species:ncbi:10116">rat</span>
###xml 1418 1421 <span type="species:ncbi:10116">rat</span>
The intention of this study was to obtain a molecular insight into the anti-inflammatory mechanism of NADPH oxidase activation by phytol in an experimental arthritis model in rats, the pristane-induced arthritis (PIA) model [21]. To analyze the in vivo effects of the NADPH oxidase activator phytol versus the effects of the arthritis-inducing compound pristane, global gene-expression profiling was performed. A biodistribution analysis of phytol was performed to determine which tissue and time point would be most relevant to investigate. Phytol was observed to accumulate slowly in inguinal lymph nodes, with peak levels being reached approximately 11 days after subcutaneous administration, which coincides with the onset period of arthritis. In the global gene-expression profiling, inguinal lymph nodes obtained 10 days after administration were analyzed. This analysis revealed several genes that were differentially expressed in rats with PIA compared with rats injected with phytol. A group of interesting genes was selected and verified by quantitative real-time PCR analysis in three further separate biological experiments, including a comparative study between the DA and DA.Ncf1E3 congenic rats. The comparison between the two strains was aimed at determining whether the selected genes were differentially expressed in the arthritis-susceptible DA rat versus the arthritis-resistant congenic DA.Ncf1E3 rat. Such data would indicate whether the NADPH oxidase-activating compound phytol is activating a pathway that is normally inactive in the absence of a fully functional Ncf1.
###end p 13
###begin p 14
By studying gene-expression profiles and performing pathway analysis, we have identified the importance of an IFN-beta-dependent pathway as one molecular mechanism for the arthritis-ameliorating efficacy of NADPH oxidase-activating compounds.
###end p 14
###begin title 15
Results
###end title 15
###begin p 16
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 353 357 <span type="species:ncbi:10116">rats</span>
The discovery that NADPH oxidase-derived ROS have disease-protecting effects in arthritis opens up new possibilities for drug development against autoimmune and inflammatory diseases. To obtain a more detailed understanding of the molecular mechanism of this regulation, gene-expression profiling experiments were performed on inguinal lymph nodes from rats with pharmacologically (phytol) and genetically (Ncf1) modified NADPH oxidase activity.
###end p 16
###begin title 17
Biodistribution and NADPH oxidase activation
###end title 17
###begin p 18
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 87 95 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 228 232 <span type="species:ncbi:10116">rats</span>
###xml 238 242 <span type="species:ncbi:10116">rats</span>
Phytol has previously been identified as a potent NADPH oxidase activator [14,20]. The in vivo distribution of phytol was analyzed and examined by subcutaneous injection of tritium-labeled phytol into the base of the tail in DA rats. The rats were killed and dissected 2, 4, 8, 11 and 17 days after administration. Various organs (inguinal lymph nodes, spleen, heart, thymus, kidney, liver, lung, fat, muscle and peripheral blood) were collected, homogenized and analyzed in a beta counter to determine tissue-incorporated tritiated phytol. Most of the administered phytol remained as a depot at the injection site (> 90%, data not shown), whereas phytol distributed to tissues was recovered mainly from the inguinal lymph nodes. Furthermore, the accumulation of phytol in the lymph nodes reached its maximum level 11 days after administration (Figure 1). No phytol was detected in peripheral blood at the time points studied or in blood collected at earlier time points (2, 6, 13 or 25 hours after administration, data not shown). Further analysis of the biodistribution of phytol at the microscopic level in the inguinal lymph nodes was performed by microautoradiography. It was shown that phytol was distributed primarily to the cortical regions and also in the sinusoidal space of the inguinal lymph nodes (data not shown). Moreover, the staining seemed to appear between cells or in the cell membrane, but not intracellularly.
###end p 18
###begin title 19
Global gene-expression profiling
###end title 19
###begin p 20
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 636 639 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 986 988 984 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1295 1297 1293 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1478 1479 1476 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 818 822 <span type="species:ncbi:10116">rats</span>
###xml 1397 1401 <span type="species:ncbi:10116">rats</span>
###xml 1465 1469 <span type="species:ncbi:10116">rats</span>
Previous results have shown that the NADPH oxidase activator phytol has ameliorating properties on arthritis when administrated prior to arthritis induction and when given as therapeutic treatment [20]. To obtain a molecular understanding of the protective effects of phytol on PIA, four groups of animals were subjected to different conditions; (i) induced arthritis by injection with pristane, (ii) injection with phytol, (iii) injection with both pristane and phytol, and (iv) no treatment. All animals were killed close to disease onset, i.e.10 days after administration. Global gene-expression profiling using chip arrays (Genechip(R);Affymetrix, Santa Clara, CA, USA) was performed on the collected inguinal lymph nodes from the described animals. The gene-expression pattern was quite different between treated rats and naive controls. Comparing any of the group of treated animals and untreated animals, > 350 differentially expressed genes were detected (at significance level p < 0.05 and absolute fold change > 1.4; data not shown). However, as the most interesting differences were to be found between the different treatments, the analysis focused on these groups. When comparing phytol-treated versus pristane-treated animals, the expression of 29 genes was significantly changed (p < 0.05, with absolute fold change > 1.4). Of these 29 genes, 13 showed expression in phytol-treated rats, whereas 16 genes showed higher expression in pristane-treated rats (Figure 2). Because more complex gene induction was observed in animals given phytol plus pristane, further studies concentrated on analyses of single-compound administrations.
###end p 20
###begin title 21
Quantitative real-time PCR validation of differentially expressed genes
###end title 21
###begin p 22
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 642 644 642 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
To minimize erroneous conclusions due to technical variability and multiple testing effects inherent to the microarray technology, as well as biological variation, quantitative real-time PCR analysis was used to validate expression profiles of nine differentially expressed genes (Table 1) in separate biological material. This verification confirmed all examined transcripts to be differentially expressed (data not shown). In addition, there was strong correlation between the fold changes detected using global gene expression and the quantitative real-time PCR analysis for the identified genes (Table 1; Pearson correlation coefficient R2 > 0.96) [22].
###end p 22
###begin title 23
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12</italic>
The genes upregulated by injections with pristane were Ass, Cxcl9 and Mmp12
###end title 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass </italic>
###xml 5 33 5 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">argininosuccinate synthetase</italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass </italic>
###xml 291 293 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 294 296 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 496 498 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 674 676 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 843 845 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 943 945 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1123 1125 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1142 1144 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1260 1262 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 833 841 <span type="species:ncbi:9606">patients</span>
###xml 1190 1198 <span type="species:ncbi:9606">patients</span>
Ass (argininosuccinate synthetase) encodes an enzyme involved in the urea cycle mediating the condensation of citrulline and aspartic acid to form arginine. The expression of Ass is induced by common pro-inflammatory cytokines (interleukin (IL)-1beta, interferon (IFN)-gamma and TNF-alpha) [23,24]. CXCL9 (Chemokine (C-X-C motif) ligand 9, also known as Mig, (monokine induced by IFN-gamma)) is a chemokine belonging to the CXC subfamily of chemokines acting through G-protein-coupled receptors [25]. These proteins have chemoattraction and growth-promoting properties and are induced by IFN-gamma and, to some extent, TNF-alpha to attract T cells to sites of inflammation [26]. Higher levels of CXCL9 expression have been observed in the synovial tissues and fluids of patients with RA compared with tissues and fluids from control patients [27]. MMP12 (matrix metalloproteinase 12) belongs to the family of matrix metalloproteinases (MMPs) [28], which are involved in cell migration and degradation of cartilage and bone by remodeling the extracellular matrix. Inducers of expression of MMPs include IL-1beta, TNF-alpha [29] and IFN-gamma [30]. Abnormal levels of MMPs have been found in patients with autoimmune disorders such as RA and multiple sclerosis [31].
###end p 24
###begin title 25
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7</italic>
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifit3</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9</italic>
The genes upregulated by phytol were Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9
###end title 25
###begin p 26
###xml 237 239 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 453 455 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 456 458 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 603 605 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 704 706 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 834 836 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 837 839 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 934 936 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 970 972 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1070 1072 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1134 1136 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1137 1139 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Best5 (bone-expressed sequence tag 5) is mainly expressed in bone marrow and spleen and has been proposed to be involved in bone formation. The cytokines IFN-alpha and IFN-gamma have been shown to induce BEST5 expression in osteoblasts [32].Interferon regulatory factor (IRF)-7 belongs to the IRF family of transcription factors involved in cell growth, antiviral defense and immune activation in lymphoid cells in spleen, thymus, and peripheral blood [33,34]. IRF7 is part of the pathway activated by viral infection to induce the production of IFN type I (IFNtalpha/beta) by a positive feedback loop [35]. IRF7 was recently reported to be the master regulator of IFN type I-dependent immune responses [36], and recent publications have shown that an IRF5 polymorphism is strongly associated with systemic lupus erythematosus (SLE) [37,38]. Interferon-induced protein with tetratricopeptide repeats (IFIT)-3 is induced by IFN-alpha [39] and IFN-beta but not IFN-gamma [40]. However, IRF-7 most probably has a dual role, being both a strong regulator of IFN expression [35] and being induced by IFN in a positive feedback regulation [35,41].
###end p 26
###begin p 27
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
The protein 2',5'-oligoadenylate synthetase (OAS)-1 belongs to the OAS family, which was one of the first groups of IFN-induced antiviral proteins to be characterized. The activation of this mechanism is induced by the IFN type I pathway, which is activated upon pathogenic invasion as part of an antiviral response [42].
###end p 27
###begin p 28
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 240 242 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Myxovirus resistance (MX)-2 has a functional role in the defense against viral infections and its expression is partly controlled by type I IFNs [43]. MX2 is induced by type I IFNs, and to a less extent by IFN-gamma and lipopolysaccharide [44].
###end p 28
###begin p 29
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
S100a9 is a small calcium-binding protein that belongs to the S100 family. It is primarily expressed by neutrophils but also by activated monocytes and macrophages [45]. S100a9 has been shown to have a chemoattractant function in inflamed tissue, attracting neutrophils and inducing the adhesion of the attracted cells [46]. Elevated levels of S100a9 have been found in the synovial fluid [47] and plasma [48] of patients with RA.
###end p 29
###begin title 30
Identification of interferon-regulated pathways
###end title 30
###begin p 31
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 602 604 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 605 607 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1005 1025 1001 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass, Cxcl9 and Mmp12</italic>
###xml 1112 1152 1104 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9</italic>
To find a connection between the differentially expressed genes bioinformatic tools (Ingenuity Pathway Analysis; Ingenuity systems Inc., CA, USA, and PathwayAssist; Stratagene, CA, USA) and literature studies were used to assign pathways for these genes. Using these analysis tools, large schematic diagrams, covering all published interactions between the identified genes and common denominators, are produced. However, in this study we chose to focus on and validate one common denominator for the regulation of the identified differentially expressed genes, i.e.Ifn types I and type II (Ifngamma) [35,49]. In addition, this stratification of the bioinformatic information was performed to make it possible to verify these findings using quantitative real-time PCR and to validate the biological importance of the identified pathway in further biological experiments. Hence, the identified central pathways for further studies included the genes increased in expression due to treatment with pristane (Ass, Cxcl9 and Mmp12), which are regulated by Ifn-gamma and genes with increased expression due to phytol (Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9), which are induced by IFN-alpha/beta.
###end p 31
###begin p 32
###xml 187 189 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 317 321 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
Both IFN-alpha/beta and IFN-gamma have an important role in the immunological response to pathogens and viruses. However, type I IFNs are mainly produced by plasmacytoid dendritic cells [50], whereas IFN-gamma is produced by macrophages, natural killer (NK) cells and activated T helper (Th) cells. Consequently, the Ifn genes were included in the panel of genes to be further studied.
###end p 32
###begin title 33
Time study
###end title 33
###begin p 34
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
To analyze how the expression of the selected genes (Table 1) varies over time, a third biological experiment was performed. In this experiment, only pristane-treated or phyto- treated animals were studied, and inguinal lymph nodes were isolated at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection. This time study enabled us to follow the expression of these genes during the development of arthritis induced by pristane (Figure 3).
###end p 34
###begin p 35
###xml 84 87 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12</italic>
###xml 149 151 149 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 731 733 731 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
The three genes associated with increased expression after pristane administration (Ass, Cxcl9 and Mmp12) showed significantly increased expression (p < 0.01) after disease onset (i.e. days 13-19 after pristane administration) compared with the phytol-treated group. Phytol induced a small increase in expression of these genes around the day of disease onset (day 8-13) and then decreased to the same low expression as seen at day 0 (Figure 4). The fact that the highest expression of these genes occurs after arthritis onset makes it plausible that the increased expression of these genes is associated with the inflammatory response. However, as seen for the expression of Cxcl9 (Figure 4B), which also increased significantly (p < 0.05) at days 3-6 after pristane injection, the expression of such genes also plays a role in the early response after injection.
###end p 35
###begin p 36
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5</italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifit3</italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1</italic>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9</italic>
###xml 161 163 161 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 338 342 <span type="species:ncbi:10116">rats</span>
All genes associated with increased expression after phytol administration (Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9) showed significantly increased expression (p < 0.05) compared with pristane (Figure 5) in the early disease-onset period (day 8-10). The expression levels then decreased to the same low level as for the pristane-treated rats.
###end p 36
###begin p 37
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a8 </italic>
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1 </italic>
###xml 167 174 167 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 178 181 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2</italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
Besides the genes described above, S100a8 and the Mx2-related gene Mx1 were also analyzed in this time study and shown to be expressed in a similar pattern to that of S100a9 and Mx2, respectively (data not shown). As these genes are closely related, only one of each was followed for further expression characterization. The expression of Ncf1 was also included in this analysis as a control. However, no marked difference in Ncf1 expression was detected between the groups of animals (data not shown).
###end p 37
###begin p 38
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 92 101 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#947; </italic>
###xml 165 167 161 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 193 202 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#945; </italic>
###xml 206 209 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 325 334 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#945; </italic>
###xml 338 346 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 469 478 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#945; </italic>
###xml 482 490 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 549 551 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 568 570 543 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 636 638 607 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 679 681 647 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 775 778 743 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 850 880 811 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3, Oas1, Mx2 </italic>
###xml 884 890 845 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9</italic>
###xml 930 931 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 943 948 904 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A, B</xref>
###xml 958 967 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#945; </italic>
###xml 971 979 928 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 1321 1322 1275 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1327 1328 1281 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 136 140 <span type="species:ncbi:10116">rats</span>
###xml 352 356 <span type="species:ncbi:10116">rats</span>
###xml 514 518 <span type="species:ncbi:10116">rats</span>
The expressions of the Ifn genes were also analyzed over time (Figure 6). The expression of Ifngamma was significantly increased in the rats injected with pristane (p < 0.01) and expression of Ifnalpha and Ifnbeta was increased after injection with phytol. To further validate the significance of the increased expression of Ifnalpha and Ifnbeta in DA rats at day 10 after treatment with phytol, RNA samples produced from all four separate experiments was analyzed for Ifnalpha and Ifnbeta expression levels in DA rats treated with either pristane (n = 19) or phytol (n = 18). This combined dataset showed an upregulation of IFN-alpha (p < 0.05) and an upregulation of IFN-beta (p < 0.01) in phytol-treated compared with pristane-treated animals. The increased expression of Ifnalpha/beta coincided with the most pronounced increase in expression of Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9, i.e. day 8-10 after treatment (Figure 5 and Figure 6A, B). Hence, Ifnalpha and Ifnbeta could be postulated to be common regulatory genes for this molecular pathway of genes that were all induced by phytol treatment. However, it should be noted that the expression levels of the studied type I interferons were very low and that the difference in expression levels could only be detected using quantitative real-time PCR (Figures 6 and 9).
###end p 38
###begin p 39
###xml 156 165 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tnf&#945; </italic>
###xml 169 174 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 328 337 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tnf&#945; </italic>
###xml 341 346 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 412 421 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tnf&#945; </italic>
###xml 490 495 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
TNF-alpha and IL-1 are other cytokines identified as important immunological regulators in the same molecular pathways as the interferons. Transcription of Tnfalpha and IL-1 is increased in macrophages activated by IFN-alpha to act synergistically with IFN-gamma in initiating a chronic inflammatory response. The expression of Tnfalpha and IL-1 was also analyzed, but only a small decrease in the expression of Tnfalpha could be observed after phytol administration, and the expression of IL-1 was below the detection limit (data not shown).
###end p 39
###begin title 40
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 52 56 <span type="species:ncbi:10116">rats</span>
Verification of Ifn type I pathway in Ncf1 congenic rats
###end title 40
###begin p 41
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 250 253 250 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 416 419 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 783 794 783 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass, Cxcl9 </italic>
###xml 798 805 798 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp-12 </italic>
###xml 860 862 860 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 927 929 927 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 135 139 <span type="species:ncbi:10116">rats</span>
###xml 253 257 <span type="species:ncbi:10116">rats</span>
###xml 265 269 <span type="species:ncbi:10116">rats</span>
###xml 366 369 <span type="species:ncbi:10116">rat</span>
###xml 1069 1072 <span type="species:ncbi:10116">rat</span>
The selected genes that were identified as being associated with either the disease state (pristane) or treatment state (phytol) of DA rats, were further analyzed in another biological experiment including a comparison between DA and congenic DA.Ncf1E3 rats. These rats carry different alleles of the Ncf1 gene, and differ dramatically in arthritis severity; the DA rat is highly susceptible and the congenic DA.Ncf1E3 is almost completely resistant to arthritis [14]. This analysis was included to study the importance of the selected genes for the difference in arthritis susceptibility caused by different Ncf1 alleles, and thus also NADPH oxidase functionality in PIA compared with phytol treatment. Administration with either pristane or phytol leads to increased expression of Ass, Cxcl9 and Mmp-12 in both strains, compared with the untreated controls (p < 0.01) (Figure 7). Further, a clear and significant difference (p < 0.001) between the pristane-treated and phytol-treated animals was observed, although no significant difference was found between the two rat strains.
###end p 41
###begin p 42
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5</italic>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7</italic>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifit3</italic>
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2</italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1 </italic>
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 117 119 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 212 214 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 225 244 225 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3 </italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9</italic>
###xml 399 423 399 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3, Mx2 </italic>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1 </italic>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 265 269 <span type="species:ncbi:10116">rats</span>
###xml 281 285 <span type="species:ncbi:10116">rats</span>
###xml 472 476 <span type="species:ncbi:10116">rats</span>
Expression of Best5, Irf7, Ifit3, Mx2, Oas1 and S100a9 were all induced by phytol, compared with untreated controls (p < 0.01). Interestingly, after pristane injection, there was significantly higher expression (p < 0.05) of Best5, Irf7, Ifit3 and Mx2 in DA.Ncf1E3 rats than in DA rats. No difference in expression levels between the strains was observed for S100a9. Overall, the gene expression of Best5, Irf7, Ifit3, Mx2 and Oas1 showed the highest expression levels in rats that had been injected with a combination of pristane and phytol (Figure 8).
###end p 42
###begin p 43
###xml 0 9 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#945; </italic>
###xml 180 182 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 198 200 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 221 229 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 255 257 248 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 421 423 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 444 453 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#947; </italic>
###xml 479 481 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 579 581 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
###xml 604 612 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 650 654 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 654 657 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 710 712 696 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 745 753 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 892 900 875 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 945 949 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 949 952 929 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 965 967 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 108 112 <span type="species:ncbi:10116">rats</span>
###xml 174 178 <span type="species:ncbi:10116">rats</span>
###xml 497 501 <span type="species:ncbi:10116">rats</span>
###xml 566 570 <span type="species:ncbi:10116">rats</span>
###xml 657 661 <span type="species:ncbi:10116">rats</span>
###xml 679 683 <span type="species:ncbi:10116">rats</span>
###xml 759 763 <span type="species:ncbi:10116">rats</span>
###xml 835 839 <span type="species:ncbi:10116">rats</span>
###xml 952 956 <span type="species:ncbi:10116">rats</span>
Ifnalpha was expressed at a lower level in both the pristane-treated and phytol-treated animals, and in the rats with combined treatment, compared with the untreated control rats (p < 0.01) (Figure 9A). The expression of Ifnbeta was significantly higher (p < 0.01) in the pristane-injected or phytol-injected groups than in the untreated control group, while the combined treatment induced even higher expression (Figure 9B). The expression of Ifngamma was significantly higher (p < 0.01) for the rats injected with pristane than for both control and phytol-treated rats (Figure 9C). Interestingly, only Ifnbeta showed different expression in the DA.Ncf1E3 rats compared with DA rats after pristane injection (p < 0.05). The expression level of Ifnbeta in DA rats after pristane injection was comparable with that of untreated control rats; however, after phytol administration, the level of Ifnbeta was increased to a level equal to that of DA.Ncf1E3 rats (Figure 9B).
###end p 43
###begin title 44
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 35 39 <span type="species:ncbi:10116">rats</span>
Cell distribution in Ncf1 congenic rats
###end title 44
###begin p 45
###xml 648 650 648 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 672 675 672 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10</xref>
###xml 1148 1156 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 414 418 <span type="species:ncbi:10116">rats</span>
The levels of different cell populations in the studied tissue may affect the outcome of gene-expression profiling. Therefore, fluorescence-activated cell-sorting (flow cytometry, BD Biosciences) analyses were performed on isolated inguinal lymph nodes to determine whether the observed differentially expressed genes could be explained by a skewed cell population. In both the pristane-treated and phytol-treated rats, the number of B and NK cells were raised compared with untreated controls, whereas the relative number of T cells were lower. Significantly more B and NK cells were observed after phytol treatment than after pristane treatment (p < 0.01, DA and DA.Ncf1E3 combined). No significant alterations in the subset of cells containing macrophages and dendritic cell populations (i.e. CD4+TCR- cells) could be detected (data not shown). No difference between the strains was observed for all of the studied groups of animals (Figure 10). These effects on cell populations could have a major impact on the gene-expression profiles, but as no difference between the strains was observed, the differentially expressed genes assigned to the Ifnbeta pathway are unlikely to be the result of differences in these cell populations.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 706 711 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 104 107 <span type="species:ncbi:10116">rat</span>
###xml 376 379 <span type="species:ncbi:10116">rat</span>
###xml 384 389 <span type="species:ncbi:10090">mouse</span>
Ncf1 is a gene encoding the activating component of the NADPH oxidase complex. By positional cloning in rat models of arthritis, a polymorphism of Ncf1 was found to regulate arthritis severity [14]. In fact, it was shown that a less functional Ncf1, and the resulting decrease in NADPH oxidase capacity to produce ROS, is a major cause of increased arthritis severity in both rat and mouse models of arthritis, an observation that challenges the general dogma of the inflammatory role of ROS. Furthermore, NADPH-activating substances have both preventive and therapeutic effects on arthritis, which opens up new approaches for disease treatment [20]. However, from the results of the positional cloning of Ncf1 and the data showing strong ameliorating effects of ROS-inducing compounds in animal models, we are still a long way from fully understanding the underlying mechanism of action.
###end p 47
###begin p 48
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
One approach to obtaining a molecular insight into a complex biological system is to use global gene-expression profiling [51]. An advantage of this method is the large set of genes that can be analyzed in the same experimental setup, making it possible to use clustering and pathway analysis of large sets of genes [52,53]. The assembled biological information can then be stratified into molecular pathways that can be studied and thoroughly validated.
###end p 48
###begin p 49
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
However, the intricate choice of time point and tissue/cell type to be selected for analysis presents a significant hurdle [54]. A further difficulty is the need for biological replicates and the genetic heterogeneity that is involved in human studies. This has naturally led to some skepticism regarding the utility of gene-expression profiling as a method to achieve an understanding of rheumatic diseases [55]. However, recent analysis of gene-expression fingerprints of individual patients with RA might give hope for this still technically evolving method for understanding complex disorders [56-59].
###end p 49
###begin p 50
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 616 617 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 139 143 <span type="species:ncbi:10116">rats</span>
###xml 1380 1385 <span type="species:ncbi:9606">human</span>
In this study, we used global gene-expression analysis and quantitative real-time PCR techniques in four separate arthritis experiments in rats to investigate the downstream effects of preventive arthritis treatment with the NADPH oxidase activator phytol. Based on biodistribution analyses of phytol after SC administration, global gene-expression analysis was performed on inguinal lymph nodes at a time point just before the estimated day of disease onset. We observed that the expression of our set of differentially expressed genes in our material varies dramatically during the disease progress (Figures 4, 5, 6). Therefore, it is necessary to have information about which time point and tissue to analyze before initiating gene-expression profiling. Furthermore, we also analyzed, in other tissues (i.e. thymus, blood and spleen) the expression of the genes identified as differentially expressed in inguinal lymph nodes, and observed that the expression levels could be quite different or even undetectable in these tissues (data not shown). As a result, it is not possible to extrapolate the information between tissues and time points. In addition, the number of biological replicates used in the compared groups should be high enough to enable statistical analysis. Altogether, these issues make these studies extremely cumbersome to perform, especially when analyzing human samples. By using animal models, a more optimized study design may be provided [60], as a number of identical (inbred) individuals under the same treatment and environmental conditions are compared and tissue collected at the same time point by the same researcher.
###end p 50
###begin p 51
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 573 576 573 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass</italic>
###xml 578 584 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12 </italic>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 663 665 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 666 668 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 813 814 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 816 818 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 820 821 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 826 828 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
###xml 1008 1010 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1328 1332 1320 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 1332 1334 1324 1326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3</sup>
###xml 1345 1346 1337 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 1351 1353 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
###xml 1366 1370 1358 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 1370 1373 1362 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 1429 1433 1421 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 1496 1501 1488 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1 </italic>
###xml 1561 1572 1553 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass, Cxcl9 </italic>
###xml 1576 1582 1568 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12 </italic>
###xml 1814 1816 1806 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1382 1386 <span type="species:ncbi:10116">rats</span>
In this study, we identified a molecular mechanism that links the protective effects observed from treatment with NADPH oxidase activators with a relevant inflammatory mechanism. However, it is not the differentially expressed genes per se that are most interesting, but the molecular pathways that can be extracted (Figure 11). From our comparison between pristane (arthritis inducer [21]) and phytol (NADPH oxidase-activating and arthritis-ameliorating compound [20]), two main pathways were identified. The pristane-induced pathway was marked by increased expression of Ass, Cxcl9 and Mmp12 (Table 1). These genes all share IFN-gamma as a common regulator [30,61,62], which was also shown to be upregulated in the inguinal lymph nodes, in a similar pattern, after induction of arthritis with pristane (Figures 4, 6C, 7 and 9C). IFN-gamma is known to effect the balance between Th1 and Th2 cells, and increased expression of this pro-inflammatory cytokine plays an important role in the progression of RA [63]. Although pristane stimulates the expression of these cytokine-regulated genes, no direct conclusions about whether these genes are involved in the cause of arthritis can be drawn, as no difference in gene expression could be seen between the arthritis-susceptible strain (DA) and the arthritis-protected strain (DA.Ncf1E3) (Figures 7 and 9C). As the DA.Ncf1E3 congenic rats carry the arthritis-protecting variant of Ncf1, one might speculate that the effect caused by the functional Ncf1 is to generate a resistance to the effect from induction of Ass, Cxcl9 and Mmp12 genes, which might otherwise contribute to the development of arthritis. Further investigation of the effect on disease regulation is needed to be able to propose a more exact role for these genes as potential markers of arthritis [64].
###end p 51
###begin p 52
###xml 11 41 11 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3, Mx2, Oas1 </italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9</italic>
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 253 255 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 256 258 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 259 261 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 535 537 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 538 540 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 541 543 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 546 551 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1 </italic>
###xml 555 559 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 667 669 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 690 696 666 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5 </italic>
###xml 845 847 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Six genes (Best5, Irf7, Ifit3, Mx2, Oas1 and S100a9) were identified as genes induced by phytol (Table 1). The common inducers of these are IFN-alpha and IFN-beta. These interferons are anti-inflammatory cytokines expressed after pathogenic infections [35,65,66]. From the gene-expression data it is not possible to determine whether IRF-7 is upregulated by an increased level of IFN-alpha/beta as a downstream feedback regulator of the IFN-alpha/beta receptor or if increased IFN-beta level is the result of an upregulation of IRF-7 [35,41,36]. Oas1 and Mx2 are both induced upon viral invasion and IFN type I activation, and are thus regulated by the same pathway [67]. The expression of Best5 can be induced by both IFN-alpha/beta and IFN-gamma, but studies have shown IFN-alpha/beta to have the strongest enhancing effect on the expression [32].
###end p 52
###begin p 53
###xml 53 61 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 79 83 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 83 86 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 150 154 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 154 157 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 190 198 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 223 225 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 336 360 330 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5, Irf7, Ifit3, Mx2 </italic>
###xml 364 369 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1 </italic>
###xml 377 378 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 454 458 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 762 764 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 765 767 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 798 800 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 885 889 869 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 933 935 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 960 963 944 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 969 974 949 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946; </italic>
###xml 1097 1101 1074 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 1174 1178 1151 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 1682 1685 1659 1662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 1687 1699 1664 1676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7, IP-10 </italic>
###xml 1703 1710 1680 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Isg-15 </italic>
###xml 1735 1737 1712 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 2206 2210 2180 2184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn </italic>
###xml 2337 2339 2311 2313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 2355 2357 2329 2331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 2552 2554 2526 2528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 2624 2627 2598 2601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 2705 2713 2676 2681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 2725 2727 2693 2695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 2933 2935 2898 2900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 3047 3049 3009 3011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 3050 3052 3012 3014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 3101 3104 3063 3066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 157 161 <span type="species:ncbi:10116">rats</span>
###xml 210 214 <span type="species:ncbi:10116">rats</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
###xml 777 782 <span type="species:ncbi:10090">mouse</span>
###xml 1044 1048 <span type="species:ncbi:10116">rats</span>
###xml 1544 1548 <span type="species:ncbi:10090">mice</span>
###xml 2642 2646 <span type="species:ncbi:10090">mice</span>
###xml 2873 2877 <span type="species:ncbi:10090">mice</span>
###xml 2918 2926 <span type="species:ncbi:9606">patients</span>
Interestingly, a clear tendency in the expression of Ifnbeta between DA and DA.Ncf1E3 strains was observed after injection with pristane, with the DA.Ncf1E3 rats having higher expression of Ifnbeta than the DA rats (Figure 9B). This difference in expression level clearly resembles the differences observed for the phytol-induced genes Best5, Irf7, Ifit3, Mx2 and Oas1 (Figure 8). It is therefore likely that the downstream effect of the polymorphism in Ncf1, as well as the therapeutic effect of phytol, involves regulation of an IFN-beta pathway. This IFN-beta-regulated gene profile is interesting with respect to similarities to the patterns that have been identified in patients with SLE and in patients with juvenile arthritis treated with anti-TNF-alpha [68-71], and in mouse models of SLE [72]. Subpopulations with active RA have also been shown to express increased levels of Ifn type I signature genes in peripheral blood [59]. These reports show an Ifnalpha/beta expression signature, which is very similar to that identified in the rats treated with phytol. However, in our study, the Ifn type I expression profile was linked to disease protection while the SLE Ifn type I profile was linked to disease progression. This may indicate that the interferon balance could be an important threshold denominator of autoimmune diseases, functioning as an essential balance for immune regulation, with an imbalance resulting in either SLE or arthritis. This is also exemplified by a recent study in which pristane was used to induce SLE in mice. In that study, chronic peritoneal administration of pristane elicited increased expression of the type I interferon-inducible genes Mx1, Irf7, IP-10 and Isg-15 as a consequence of SLE [72]. However, despite the similarities in expression pattern, it must be noted that the SLE studies were performed on tissues other than inguinal lymph nodes and on established disease, so that differences in gene profiles could be caused by tissue differences or time-dependent regulation. Also interesting is the fact that the present study points towards a disease-ameliorating pathway that is regulated by IFN-beta. Therefore, as the present observation of increased Ifn type I signature genes was observed to be a signal for prevention of disease onset, in contrast to the studies in ongoing SLE [68]and arthritis [59], one might speculate that increased IFN type I regulation is a way to downregulate an ongoing immune response. Such an attempt to limit the inflammatory response has been suggested previously [73], and has also been indicated by experiments in our laboratory using Ifnbeta-deficient mice, where a prolonged arthritis severity was observed due to Ifnbeta deficiency [74]. In fact, treatment with recombinant IFN-beta significantly reduces cartilage destruction and bone destruction in collagen-induced arthritis in mice, which suggested a beneficial effect in patients also [70]. However, to date no positive outcome of clinical trials using recombinant IFN-beta in RA has been presented [75,76]. As we have shown that the effect of phytol on Ifnbeta-related genes is time-dependent and also correlates with the biodistribution of phytol to the inguinal lymph nodes, it is possible that tissue distribution as well as the dose and frequency of administration are crucial for the efficacy of arthritis treatment via this pathway.
###end p 53
###begin p 54
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 207 209 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
The data presented here, together with gene-expression profiles of SLE, [68-71] and arthritis [59] strongly suggests the importance of the IFN-alpha/beta pathway as a key mechanism in autoimmune conditions [77].
###end p 54
###begin p 55
###xml 294 296 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
The fact that no difference in cell populations was observed to explain the differential levels of mRNA for IFN-beta-regulated genes does not prove that alterations in cell populations in the inguinal lymph nodes are not crucial. As IFN-beta is mainly produced by plasmacytoid dendritic cells [77], which were not specifically addressed in this study, more careful analysis of this cell population might provide further insight into the disease-protecting effects of phytol in arthritis.
###end p 55
###begin p 56
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5F</xref>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 169 172 169 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8F</xref>
###xml 244 252 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 260 262 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 290 297 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 377 384 371 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 461 464 455 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 507 509 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 510 512 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 539 546 533 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 859 866 853 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 898 906 892 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 47 51 <span type="species:ncbi:10116">rats</span>
###xml 172 176 <span type="species:ncbi:10116">rats</span>
Increased expression of S100a9 was observed in rats treated with phytol (Figure 5F). However, the expression of S100a9 did not show any difference between DA and DA.Ncf1E3 rats (Figure 8F), and the expression profile was not similar to that of Ifnbeta (Figure 9B). As a result, we consider S100a9 not to be regulated by IFN-beta. It is more likely that the increased levels of S100a9 expression is a direct effect of increased concentrations of intracellular Ca2+ induced by the NADPH oxidase-produced ROS [78,79]. Increased expression of S100a9 is mostly reported to be proinflammatory. However, this knowledge is based on analyses from tissues and blood during ongoing inflammation, while these studies analyzed inguinal lymph nodes prior to disease onset. Hence, the expression levels for different timepoints of the disease process could differ. Even so, S100a9 may be a good biomarker for the in vivo efficacy of administered phytol as an activator of NADPH oxidase specifically in lymph node tissues.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
By targeting the NADPH oxidase complex with activating compounds such as phytol, we highlight a new mechanism to treat autoimmune conditions such as arthritis. By extracting and verifying a relevant biological molecular mechanism from gene-expression profiling data, we also indicate a plausible relation between increased levels of ROS and an anti-inflammatory response regulated by an IFN-beta pathway. The use of gene-expression profiling to compare treatments in animal models of complex diseases also points to a useful pharmacogenomic approach to extract relevant information about the mechanism of action and to identify potential molecular biomarkers to be used in future animal experiments and clinical trials.
###end p 58
###begin title 59
Methods
###end title 59
###begin title 60
Animals
###end title 60
###begin p 61
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 479 489 479 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 614 635 614 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycoplasma pulmonalis</italic>
###xml 3 7 <span type="species:ncbi:10116">rats</span>
###xml 198 202 <span type="species:ncbi:10116">rats</span>
###xml 495 499 <span type="species:ncbi:10116">rats</span>
###xml 542 554 <span type="species:ncbi:11191">Sendai virus</span>
###xml 556 569 <span type="species:ncbi:11599">Hantaan virus</span>
###xml 584 592 <span type="species:ncbi:10891">reovirus</span>
DA rats used in the microarray analysis, the first verifying quantitative real-time PCR study, the time study and the biodistribution study were purchased from Harlan Netherlands, and the DA.Ncf1E3 rats with background origin from Zentralinstitut Fur Versuchstierzucht, Hannover, Germany [80,81]. All animals were kept in a climate-controlled environment with 12-hour light/dark cycles, housed in polystyrene cages containing wood shavings and fed standard rodent chow and water ad libitum. The rats were free from common pathogens including Sendai virus, Hantaan virus, coronavirus, reovirus, cytomegalovirus and Mycoplasma pulmonalis. The experiments were approved by the local ethics committees (Goteborg, Swedish license 230/2003 and Malmo/Lund, Swedish license M70/2004).
###end p 61
###begin title 62
Induction and evaluation of arthritis
###end title 62
###begin p 63
###xml 540 542 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 140 144 <span type="species:ncbi:10116">rats</span>
###xml 535 538 <span type="species:ncbi:10116">rat</span>
Pristane (Sigma-Aldrich, St. Louis, MO, USA) and/or phytol (3,7,11,15-tetramethyl-2-hexadecene-1-ol) (Sigma-Aldrich) were injected into the rats (age 8-12 weeks) by a single subcutaneous injection of 200 muL at the base of the tail. Arthritis development was monitored with a macroscopic scoring system of the four limbs ranging from 0 to 15 (1 point for each swollen or red toe, 1 point for midfoot digit or knuckle, 5 points for a swollen ankle). The scores of the four paws were added, yielding a maximum total score of 60 for each rat [82].
###end p 63
###begin p 64
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 194 197 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">later</italic>
###xml 108 112 <span type="species:ncbi:10116">rats</span>
###xml 209 213 <span type="species:ncbi:10116">rats</span>
###xml 382 386 <span type="species:ncbi:10116">rats</span>
In the global gene-expression profiling and the first verifying quantitative real-time PCR experiment, five rats per group were used. In the comparative experiment between the DA and the DA.Ncf1E3 strain, 4-5 rats per group were used. In all three experiments, the analyzed groups were; naive controls, pristane-treated, phytol-treated and pristane plus phytol-treated animals. All rats were killed 10 days after injection. In the time-resolution study for comparison between pristane and phytol, four animals from each group were killed at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection. The inguinal lymph nodes were immediately surgically removed and stored in a tissue-storage reagent (RNA later; Qiagen, Germany).
###end p 64
###begin title 65
Biodistribution
###end title 65
###begin p 66
###xml 3 7 <span type="species:ncbi:10116">rats</span>
###xml 146 149 <span type="species:ncbi:10116">rat</span>
###xml 155 159 <span type="species:ncbi:10116">rats</span>
###xml 865 869 <span type="species:ncbi:10116">rats</span>
###xml 944 947 <span type="species:ncbi:10116">rat</span>
DA rats were injected with 200 muL phytol (Sigma-Aldrich) mixed with tritiated phytol (Moravek Biochemicals, CA, USA) to a final dose of 167 muCi/rat. The rats, four each day, were killed at 2, 4, 8, 11 or 17 days after injection, and the inguinal lymph nodes, spleen, heart, thymus, kidney, liver, lung, adipose tissue, muscle, injection-site tissue and blood were collected in equal amounts of saline solution (blood samples had heparin added to prevent coagulation) in pre-weighed tubes. The tissues were weighed, homogenized, and mixed with ready-safe scintillation liquid (Beckman Coulter, CA, USA). Tissue distribution of phytol was determined as counts per minute (cpm) of tritium using a beta counter (LKB Wallac, Turku, Finland) and cpm/g tissue was determined as the relative distribution of phytol. Microautoradiography was performed on three individual rats 10 days after subcutaneous administration with tritiated phytol (167 muCi/rat). The inguinal lymph nodes were snap-frozen in liquid nitrogen and shipped on dry ice to Quest Pharmaceutical Services (Newark, DE, USA). The frozen lymph nodes were embedded in optimum cutting temperature (OCT) embedding media (VWR international, Bristol, CT, USA) for cryosectioning. Sections of 10 mum thickness were heated at 50degreesC for 10 minutes, coated with photographic emulsion (Kodak NTB; Kodak, New Haven, CT, USA) and dried. The coated slides were exposed at 4degreesC in lightproof boxes. The exposed slides were stained with hematoxylin and eosin and developed for tritium labeling.
###end p 66
###begin title 67
Flow cytometry analysis
###end title 67
###begin p 68
###xml 97 100 <span type="species:ncbi:10116">rat</span>
Single-cell suspensions were made from inguinal lymph nodes and cells were stained with the anti-rat antibodies OX-1 (anti-LCA, lymphocytes), OX-33 (anti-CD45RA, B-cells), and R73 (anti-alphabetaTCR, T cells) (all BD Pharmingen, San Diego, CA, USA), and with 3.2.3 (anti-NKRP1, NK cells, produced from an in-house hybridoma) for 30 minutes at 4degreesC. After washing with phosphate-buffered saline (PBS), cells were resuspended in PBS and analyzed in a FACSorter (Becton Dickinson, San Jose, CA, USA). Gates were set for the relevant cell type and analysed as percentage of total lymphocytes.
###end p 68
###begin title 69
RNA isolation
###end title 69
###begin p 70
###xml 79 83 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Total RNA from inguinal lymph nodes was isolated using a commercial kit (RNeasy(R) Mini Kit; Qiagen, Germany). The protocol for animal tissues was followed with the addition of the optional DNase digestion (RNase-Free DNase Set; Qiagen). The RNA yield was quantified spectrophotometrically (RNA 6000 Nano assay Kit;Agilent Technologies, Palo Alto, CA, USA) and the quality analyzed (2100 Bioanalyzer; Agilent). The average ratio between 28S/18S rRNA was 2.2, indicating high RNA quality. All RNA and cDNA samples were stored at -80degreesC.
###end p 70
###begin title 71
Preparation of cRNA, hybridization and data analysis
###end title 71
###begin p 72
###xml 376 385 375 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 703 707 696 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 860 864 851 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1003 1007 992 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1179 1181 1166 1168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1209 1211 1196 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1260 1262 1247 1249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1383 1385 1370 1372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1685 1686 1672 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1920 1922 1907 1909 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 707 710 <span type="species:ncbi:10116">Rat</span>
###xml 1420 1424 <span type="species:ncbi:10116">rats</span>
###xml 1458 1462 <span type="species:ncbi:10116">rats</span>
###xml 1507 1510 <span type="species:ncbi:10116">rat</span>
In total, 10 mug of total RNA spiked with poly-A controls (pGIBS-TRP, pGIBS-THR, and pGIBS-LYS; American Type Culture Collection) was converted to cDNA, using a T7 promoter-polyT primer (Affymetrix, Santa Clara, CA, USA) and the reverse transcriptase Superscript II (Invitrogen, Paisley, UK), followed by a second-strand cDNA synthesis (Invitrogen). Double- stranded cDNA was in vitro transcribed to biotinylated cRNA (IVT labelling kit; Affymetrix) and then fragmented. The fragmented cRNA was mixed with hybridization spike controls (oligonucleotide B2 and a cRNA cocktail: BioB, BioC, BioD, and Cre; Affymetrix,). Aliquots of each sample were hybridized (16 hours at 45degreesC) to an array (GeneChip(R) Rat Expression Set 230A arrays; Affymetrix). The arrays were subsequently washed, stained and scanned according the manufacturer's instructions (GeneChip(R) Expression Analysis Technical Manual; Affymetrix). The data were analyzed using specific sofware (Robust Multi-Chip Analysis in GeneTraffic(R) UNO version 3.2-11; Stratagene, La Jolla, CA, USA, and Spotfire DecisionSite for Functional Genomics, version 8.1;Spotfire Inc., Goteborg, Sweden). The intensities were log2 transformed and the mean log2 intensity for each group calculated. The mean log2 fold change was calculated for the phytol-treated animals versus the pristane-treated animals by subtracting the mean log2 intensity for the pristane-treated rats from that for the phytol-treated rats. The total number of probe sets in the used rat Affymetrix chips was 15 923, and the average present call was 45%. Statistical significance of the difference in gene expression was determined using the two-sided Student's t-test. A transcript was considered differentially expressed if the mean absolute fold change was > 1.4 and the p value < 0.05. In addition, the mean intensity in the group showing the highest expression should be > 75. The average log2 fold change between the animals treated with phytol plus pristane versus the animals treated with pristane alone and the corresponding statistical analysis were also calculated, although these data were not used to identify differentially expressed genes.
###end p 72
###begin title 73
Accession numbers
###end title 73
###begin p 74
The global gene-expression profiling data is deposited on-line [ArrayExpress: E-MEXP-78].
###end p 74
###begin title 75
Quantitative real-time PCR
###end title 75
###begin p 76
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 387 391 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 456 459 443 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inf</italic>
###xml 721 723 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 729 746 713 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arbp (alias 36B4)</italic>
###xml 780 782 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
The primers used in the quantitative real-time PCR were designed using software (Primer Express 2.1; Applied Biosystems, Foster City, CA, USA) and the sequences are listed in Table 2. Total RNA (5 mug) was transcribed to cDNA using a commercial system (SuperScripttrade mark First Strand Synthesis System; Invitrogen). The PCR reaction was performed in a 25 muL volume including 1 x SYBR(R) Green (Applied Biosystems) and 400 nM of each primer, except for Infbeta, for which 800 nM of each primer was used. All reactions were performed in duplicate, amplified and quantified (ABI 7000 Sequence Detection System; Applied Biosystems). The relative quantities of mRNA were calculated according to the standard curve method [83] and Arbp (alias 36B4), was used as endogenous control [84].
###end p 76
###begin title 77
Statistics
###end title 77
###begin p 78
###xml 160 162 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 173 175 171 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 190 192 188 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Quantitative data is expressed as mean +/- SEM and significance analysis was performed using two-sided Student's T-test. * Represents a significance value of * p < 0.05, ** p < 0.01 and *** p < 0.001.
###end p 78
###begin title 79
Authors' contributions
###end title 79
###begin p 80
PO, AN, MH and EN contributed to the design and performed the experiments, collected and interpreted the data, and wrote the manuscript. SA and AB performed the real-time PCR under supervision of AN and PO. RH contributed to the study design, interpretation of collected data and the writing of the paper.
###end p 80
###begin title 81
Accession numbers
###end title 81
###begin p 82
The global gene-expression profiling data is deposited at ArrayExpress (accession number E-MEXP-78).
###end p 82
###begin title 83
Acknowledgements
###end title 83
###begin p 84
We thank Camilla Bernhardsson for excellent animal experiments and Andrew Browning for critically reading the manuscript. This work is supported by the Craaford Foundation; Lundberg Foundation; the Kock and Osterlund Foundations; The Swedish Association Against Rheumatism; The Swedish Medical Research Council; the Swedish Foundation for Strategic Research; the European Union (grant no. EUROME QLG1-CT2001-01407), and the 6th Framework Program of the European Union, NeuroproMiSe (grant no. LSHM-CT-2005-01863) and AUTOCURE, (grant no. LSHM-CT-2005-018661). This research was supported by the European Community's FP6 funding. This publication reflects only the author's views. The European Community is not liable for any use that may be made of the information herein.
###end p 84
###begin article-title 85
Evolving concepts of rheumatoid arthritis
###end article-title 85
###begin article-title 86
The epidemiology of rheumatoid arthritis
###end article-title 86
###begin article-title 87
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England
###end article-title 87
###begin article-title 88
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
###end article-title 88
###begin article-title 89
Methotrexate in rheumatoid arthritis. An update
###end article-title 89
###begin article-title 90
Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
###end article-title 90
###begin article-title 91
Development of anti-TNF therapy for rheumatoid arthritis
###end article-title 91
###begin article-title 92
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
###end article-title 92
###begin article-title 93
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
###end article-title 93
###begin article-title 94
###xml 90 98 <span type="species:ncbi:9606">patients</span>
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
###end article-title 94
###begin article-title 95
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis
###end article-title 95
###begin article-title 96
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis
###end article-title 96
###begin article-title 97
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis
###end article-title 97
###begin article-title 98
###xml 81 85 <span type="species:ncbi:10116">rats</span>
Positional identification of Ncf1 as a gene that regulates arthritis severity in rats
###end article-title 98
###begin article-title 99
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
###end article-title 99
###begin article-title 100
###xml 99 103 <span type="species:ncbi:10116">rats</span>
Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats
###end article-title 100
###begin article-title 101
Assembly of the phagocyte NADPH oxidase
###end article-title 101
###begin article-title 102
T cell surface redox levels determine T cell reactivity and arthritis susceptibility
###end article-title 102
###begin article-title 103
###xml 88 92 <span type="species:ncbi:10116">rats</span>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Ncf1 (p47phox) polymorphism determines oxidative burst and the severity of arthritis in rats and mice
###end article-title 103
###begin article-title 104
A New Arthritis Therapy with Oxidative Burst Inducers
###end article-title 104
###begin article-title 105
###xml 30 34 <span type="species:ncbi:10116">rats</span>
Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes
###end article-title 105
###begin article-title 106
Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR
###end article-title 106
###begin article-title 107
Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle
###end article-title 107
###begin article-title 108
###xml 126 130 <span type="species:ncbi:10116">rats</span>
Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analyses
###end article-title 108
###begin article-title 109
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Mig chemokine: biochemical and functional characterization
###end article-title 109
###begin article-title 110
###xml 184 189 <span type="species:ncbi:9606">human</span>
Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils
###end article-title 110
###begin article-title 111
CXCR3 and CCR5 ligands in rheumatoid arthritis synovium
###end article-title 111
###begin article-title 112
Matrix metalloproteinases: a tail of a frog that became a prince
###end article-title 112
###begin article-title 113
###xml 74 79 <span type="species:ncbi:9606">human</span>
Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages
###end article-title 113
###begin article-title 114
###xml 63 69 <span type="species:ncbi:10090">murine</span>
Interferon gamma induction of pulmonary emphysema in the adult murine lung
###end article-title 114
###begin article-title 115
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis
###end article-title 115
###begin article-title 116
Best5: a novel interferon-inducible gene expressed during bone formation
###end article-title 116
###begin article-title 117
Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes
###end article-title 117
###begin article-title 118
###xml 58 76 <span type="species:ncbi:10376">Epstein-Barr virus</span>
IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency
###end article-title 118
###begin article-title 119
The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors
###end article-title 119
###begin article-title 120
IRF-7 is the master regulator of type-I interferon-dependent immune responses
###end article-title 120
###begin article-title 121
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus
###end article-title 121
###begin article-title 122
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
###end article-title 122
###begin article-title 123
Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region
###end article-title 123
###begin article-title 124
###xml 39 44 <span type="species:ncbi:9606">human</span>
IFI60/ISG60/IFIT4, a new member of the human IFI54/IFIT2 family of interferon-stimulated genes
###end article-title 124
###begin article-title 125
Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction
###end article-title 125
###begin article-title 126
Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro
###end article-title 126
###begin article-title 127
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope
###end article-title 127
###begin article-title 128
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Mx2 gene: organization, mRNA expression and the role of the interferon-response promoter in its regulation
###end article-title 128
###begin article-title 129
Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9)
###end article-title 129
###begin article-title 130
Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion
###end article-title 130
###begin article-title 131
###xml 59 67 <span type="species:ncbi:9606">patients</span>
The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis
###end article-title 131
###begin article-title 132
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases
###end article-title 132
###begin article-title 133
Interferons as pathogenic effectors in autoimmunity
###end article-title 133
###begin article-title 134
Interferon-producing cells: on the front line in immune responses against pathogens
###end article-title 134
###begin article-title 135
Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies
###end article-title 135
###begin article-title 136
DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets
###end article-title 136
###begin article-title 137
Discovery and analysis of inflammatory disease-related genes using cDNA microarrays
###end article-title 137
###begin article-title 138
Genes and goals: an approach to microarray analysis in autoimmunity
###end article-title 138
###begin article-title 139
Progress and problems in defining susceptibility genes for rheumatic diseases
###end article-title 139
###begin article-title 140
Peripheral blood gene expression profiling in rheumatoid arthritis
###end article-title 140
###begin article-title 141
A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells
###end article-title 141
###begin article-title 142
###xml 130 133 <span type="species:ncbi:10116">rat</span>
Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model
###end article-title 142
###begin article-title 143
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Rheumatoid Arthritis subtypes identified by genomic profiling of peripheral blood cells: Assignment of a type I interferon signature in a subpopulation of patients
###end article-title 143
###begin article-title 144
The genetics of rheumatoid arthritis and the need for animal models to find and understand the underlying genes
###end article-title 144
###begin article-title 145
A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines
###end article-title 145
###begin article-title 146
###xml 62 67 <span type="species:ncbi:9606">human</span>
Expression of the citrulline-nitric oxide cycle in rodent and human pancreatic beta-cells: induction of argininosuccinate synthetase by cytokines
###end article-title 146
###begin article-title 147
Role of cytokines in rheumatoid arthritis
###end article-title 147
###begin article-title 148
Molecular profiling approaches for identifying novel biomarkers
###end article-title 148
###begin article-title 149
IFNs and STATs in innate immunity to microorganisms
###end article-title 149
###begin article-title 150
The growing family of interferon regulatory factors
###end article-title 150
###begin article-title 151
How cells respond to interferons
###end article-title 151
###begin article-title 152
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
###end article-title 152
###begin article-title 153
###xml 35 40 <span type="species:ncbi:9606">human</span>
The emerging role of interferon in human systemic lupus erythematosus
###end article-title 153
###begin article-title 154
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
###end article-title 154
###begin article-title 155
Cross-regulation of TNF and IFN-alpha in autoimmune diseases
###end article-title 155
###begin article-title 156
Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane)
###end article-title 156
###begin article-title 157
IFN-beta in rheumatoid arthritis
###end article-title 157
###begin article-title 158
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice
###end article-title 158
###begin article-title 159
###xml 130 138 <span type="species:ncbi:9606">patients</span>
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
###end article-title 159
###begin article-title 160
The effects of interferon beta treatment on arthritis
###end article-title 160
###begin article-title 161
Interferons alpha and beta as immune regulators - a new look
###end article-title 161
###begin article-title 162
Interleukin-8 primes oxidative burst in neutrophil-like HL-60 through changes in cytosolic calcium
###end article-title 162
###begin article-title 163
Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation
###end article-title 163
###begin article-title 164
Identification and isolation of dominant susceptibility loci for pristane-induced arthritis
###end article-title 164
###begin article-title 165
Positional cloning of Ncf1 - a piece in the puzzle of arthritis genetics
###end article-title 165
###begin article-title 166
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
Genetic analysis of mouse models for rheumatois arthritis
###end article-title 166
###begin article-title 167
###xml 72 77 <span type="species:ncbi:9606">human</span>
36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO
###end article-title 167
###begin title 168
Figures and Tables
###end title 168
###begin p 169
###xml 0 133 0 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tissue distribution of tritium-labeled phytol in rats. Biodistribution was estimated as relative counts per minute per gram of tissue</bold>
###xml 49 53 <span type="species:ncbi:10116">rats</span>
Tissue distribution of tritium-labeled phytol in rats. Biodistribution was estimated as relative counts per minute per gram of tissue. A large fraction of phytol remained as a depot in the injection site (> 90%, not shown). Besides that, the inguinal lymph nodes were the primary tissue for accumulation of phytol. The distribution of phytol to the inguinal lymph nodes showed the highest accumulation > 1 week after injection and showed a reduction after 2 weeks. Values are means from groups of four animals.
###end p 169
###begin p 170
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hierarchical clustering of differentially expressed genes in phytol-treated compared with pristane-treated rats</bold>
###xml 398 400 398 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 479 481 479 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 107 111 <span type="species:ncbi:10116">rats</span>
###xml 204 207 <span type="species:ncbi:10116">rat</span>
###xml 595 598 <span type="species:ncbi:10116">rat</span>
Hierarchical clustering of differentially expressed genes in phytol-treated compared with pristane-treated rats. Euclidean distance was used as a similarity measure. Each column represents one individual rat, and each horizontal stripe represents a gene transcript. The Affymetrix probe set identification, the gene symbol, the average fold change (FC) for phytol versus pristane together with the p value, and the average fold change for phytol/pristane versus pristane and its p value are given to the right. The colors in the clustering represent the gene-expression level in each individual rat compared with the average expression in all arrays, where green indicates low expression and red represents high expression.
###end p 170
###begin p 171
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Arthritis development in rats after subcutaneous administration of pristane (circles) or phytol (squares) in the time study experiment</bold>
###xml 302 303 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 313 315 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 25 29 <span type="species:ncbi:10116">rats</span>
Arthritis development in rats after subcutaneous administration of pristane (circles) or phytol (squares) in the time study experiment. Only animals injected with pristane developed arthritis. Values are means +/- SEM from groups of four animals. Levels of significance were calculated using Student's t-test (***p < 0.001).
###end p 171
###begin p 172
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass</italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12 </italic>
###xml 0 177 0 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The relative mRNA expression of (A) <italic>Ass</italic>, (B) <italic>Cxcl9 </italic>and (C) <italic>Mmp12 </italic>in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares)</bold>
###xml 288 289 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 297 299 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 309 311 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 322 324 320 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
The relative mRNA expression of (A) Ass, (B) Cxcl9 and (C) Mmp12 in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares). Values are means +/- SEM from groups of four animals. Levels of significance were calculated using Student's t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
###end p 172
###begin p 173
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5</italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifit3</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1</italic>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 90 97 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 0 209 0 209 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The relative mRNA expression of (A) <italic>Best5</italic>, (B) <italic>Irf7</italic>, (C) <italic>Ifit3</italic>, (D) <italic>Oas1</italic>, (E) <italic>Mx2 </italic>and (F) <italic>S100a9 </italic>in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares)</bold>
###xml 320 321 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 329 331 327 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 341 343 339 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
The relative mRNA expression of (A) Best5, (B) Irf7, (C) Ifit3, (D) Oas1, (E) Mx2 and (F) S100a9 in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares). Values are means +/- SEM from groups of four animals. Levels of significance were calculated using Student's t-test (*p < 0.05; **p < 0.01).
###end p 173
###begin p 174
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 50 58 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 66 75 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#947; </italic>
###xml 0 187 0 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The relative mRNA expression of (A) <italic>Ifn</italic>&#945;, (B) <italic>Ifn&#946; </italic>and (C) <italic>Ifn&#947; </italic>in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares)</bold>
###xml 298 299 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 308 310 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
The relative mRNA expression of (A) Ifnalpha, (B) Ifnbeta and (C) Ifngamma in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares). Values are means +/- SEM from groups of four animals. Levels of significance were calculated using Student's t-test (**p < 0.01).
###end p 174
###begin p 175
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 86 89 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass</italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9</italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12 </italic>
###xml 0 163 0 163 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene-expression comparison between DA (open bars) and DA. <italic>Ncf1</italic><sup>E3 </sup>(filled bars) of (A) <italic>Ass</italic>, (B) <italic>Cxcl9</italic>, and (C) <italic>Mmp12 </italic>in inguinal lymph nodes 10 days after injection</bold>
Gene-expression comparison between DA (open bars) and DA. Ncf1E3 (filled bars) of (A) Ass, (B) Cxcl9, and (C) Mmp12 in inguinal lymph nodes 10 days after injection. Values are means +/- SEM of 4-5 animals per group. No significant difference between the strains was detected.
###end p 175
###begin p 176
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Best5</italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Irf7</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifit3</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oas1</italic>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx2 </italic>
###xml 140 147 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S100a9 </italic>
###xml 0 194 0 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene-expression comparison between DA (open bars) and DA. <italic>Ncf1</italic><sup>E3 </sup>(filled bars) of (A) <italic>Best5</italic>, (B) <italic>Irf7</italic>, (C) <italic>Ifit3</italic>, (D) <italic>Oas1</italic>, (E) <italic>Mx2 </italic>and (F) <italic>S100a9 </italic>in inguinal lymph nodes 10 days after injection</bold>
###xml 322 323 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 331 333 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Gene-expression comparison between DA (open bars) and DA. Ncf1E3 (filled bars) of (A) Best5, (B) Irf7, (C) Ifit3, (D) Oas1, (E) Mx2 and (F) S100a9 in inguinal lymph nodes 10 days after injection. Values are means +/- SEM of 4-5 animals per group. Levels of significance between the strains were calculated using Student's t-test (*p < 0.05).
###end p 176
###begin p 177
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 86 89 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 100 108 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
###xml 116 125 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#947; </italic>
###xml 0 172 0 161 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene-expression comparison between DA (open bars) and DA. <italic>Ncf1</italic><sup>E3 </sup>(filled bars) of (A) <italic>Ifn</italic>&#945;, (B) <italic>Ifn&#946; </italic>and (C) <italic>Ifn&#947; </italic>in inguinal lymph nodes 10 days after injection</bold>
###xml 300 301 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 309 311 296 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Gene-expression comparison between DA (open bars) and DA. Ncf1E3 (filled bars) of (A) Ifnalpha, (B) Ifnbeta and (C) Ifngamma in inguinal lymph nodes 10 days after injection. Values are means +/- SEM of 4-5 animals per group. Levels of significance between the strains were calculated using Student's t-test (*p < 0.05).
###end p 177
###begin p 178
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative (%) number of lymphocytes</bold>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
Relative (%) number of lymphocytes. Comparison between DA (open bars) and DA.Ncf1E3 (filled bars) of (A) B cells, (B) T cells and (C) NK cells in inguinal lymph nodes 10 days after treatment injection. Values are means +/- SEM of 4-5 animals per group. No significant difference between the strains was detected.
###end p 178
###begin p 179
###xml 0 132 0 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic representation of the differentially expressed genes and how they are induced upon injection by (A) pristane or (B) phytol</bold>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 500 503 497 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn</italic>
###xml 535 538 528 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ass</italic>
###xml 540 546 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcl9 </italic>
###xml 550 555 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mmp12</italic>
###xml 705 709 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ncf1</italic>
###xml 709 712 702 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E3 </sup>
###xml 737 744 730 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 213 216 <span type="species:ncbi:10116">rat</span>
###xml 931 935 <span type="species:ncbi:10116">rats</span>
Schematic representation of the differentially expressed genes and how they are induced upon injection by (A) pristane or (B) phytol. The molecular pathway that is shared between the arthritis resistant DA.Ncf1E3 rat strain and the arthritis treatment achieved with phytol is the Ifn-beta-dependent pathway, which results in the upregulation of Best5, Irf7, Ifit3, Oas1 and Mx2. The inflammatory arthritis that is induced by an injection with pristane is characterized by increased expression of the Ifngamma-connected signature genes Ass, Cxcl9 and Mmp12, which potentially could be used as molecular markers for an initiating inflammatory response. As this pathway is also induced by pristane in the DA.Ncf1E3 strain this upregulation per se does not cause arthritis. Most important in this mechanism is how administration of phytol induces arthritis protection via the Ifn-beta-regulated pathway in the arthritis-susceptible DA rats.
###end p 179
###begin p 180
Differentially expressed genes selected for further studies of the mechanism involved in pristane-induced arthritis and treatment with phytol.
###end p 180
###begin p 181
###xml 131 135 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
The genes were chosen based on the difference in expression levels between phytol and pristane treatment in the Affymetrix Genechip(R) analysis.
###end p 181
###begin p 182
*Phytol versus pristane.
###end p 182
###begin p 183
Primers used for the quantitative real-time PCR.
###end p 183
###begin p 184
###xml 76 84 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ifn&#946; </italic>
The final concentration of each primer in the sample was 400 nM, except for Ifnbeta 1, for which 800 nM was used.
###end p 184
###begin p 185
FP, forward primer; RP, reverse primer.
###end p 185

